Aurealis Therapeutics Announces Positive Blinded Evaluator Efficacy Results of "DIAMEND" Phase-2 Randomized Controlled Trial (NCT06111183 / EU CT 2022-502048-10-00) with AUP-16, a multi-targeting cell & gene therapy for DFUs and other chronic wounds. Results of the study show that AUP-16 Tripling the Complete Wound Closure Rate in Patients with Chronic Diabetic Foot Ulcers with prior wound dur

Macrogen Europe has expanded the capabilities of its Amsterdam laboratory by introducing DNA and RNA extraction from blood samples, available starting January 2, 2026. This new implementation provides a faster and more accessible option for researchers and biotech partners, including the Swiss biotech community.

MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive topline results from the Phase 2 clinical trial SUISSE-MPC2 (NCT05534269) evaluating its novel proprietary muscle precursor cell (MPC)-based tissue-engineered therapy platform in female stress urinary incontinence (SUI). The study met both its primary and secondary endpoints (p<0.0001), demonstrating significant, cl

Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001) All secondary efficacy endpoints met (p<0.0001), including End of Progression™1 (median 17.47 minutes) and complete symptom resolution (median 11.95 hours) Well-tolerated safety profile of deucrictibant confirmed Efficacy and safety outcomes consistent across

Results presented at the 18th Clinical Trials in Alzheimer's Disease (CTAD) meeting, San Diego, December 1-4 VNA-318, an oral brain-penetrant small molecule therapeutic modulates a novel target to reduce inflammation and improve mitochondrial function First-in-human trial showed a highly favourable safety profile, with VNA-318 well tolerated across all dose levels without any safety concerns Singl